Metformin Impact on Maternal and Infant Cardiometabolic Health (MIMICH), an open-label randomised controlled trial, and Metformin Impact on Maternal and Cardiometabolic Health After Pregnancy (MIMICH II).

ABSTRACT:

Background

Whilst women with diabetes are at risk of having a pregnancy complicated by foetal macrosomia, a small but important minority of women develop placental dysfunction leading to a small for gestational age infant (SGA < 10th centile) (20%) and/or the development of pre-eclampsia (12-18%) which may in some cases require preterm birth. In the UK, currently, metformin is offered as first line to treat diabetes during pregnancy, regardless of the risk of placental disease; however, the effect of metformin on placental function and foetal growth remains unclear. Metformin Impact on Maternal and Infant Cardiometabolic Health (MIMICH) and Metformin Impact on Maternal and Infant Cardiometabolic Health After Pregnancy (MIMICH II) aim to better understand the impact of metformin in

SUBMITTER: Amica-Carpenter A 

PROVIDER: S-EPMC12535036 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature